LIFECORE BIOMEDICAL, INC. Financing Receivable, after Allowance for Credit Loss
LIFECORE BIOMEDICAL, INC. (LFCR) had Financing Receivable, after Allowance for Credit Loss of $10.00 million as of 2025-05-25, per its 10-KT filed 2026-03-16.
Financial Statements › Balance Sheet › Assets › Financing Receivable, after Allowance for Credit Loss
us-gaap:NotesReceivableNet · last filed 2026-03-16
- 2025-05-25: Financing Receivable, after Allowance for Credit Loss $10.00M.
- 2020-05-31: Financing Receivable, after Allowance for Credit Loss $0.00.
- 2019-05-26: Financing Receivable, after Allowance for Credit Loss $2.00M.
- 2018-05-27: Financing Receivable, after Allowance for Credit Loss $2.70M.
| Period end | Financing Receivable, after Allowance for Credit Loss |
|---|---|
| 2025-05-25 | $10.00M 10-KT · filed 2026-03-16 |
| 2020-05-31 | $0.00 10-K · filed 2020-08-14 |
| 2019-05-26 | $2.00M 10-K · filed 2020-08-14 |
| 2018-05-27 | $2.70M 10-K · filed 2019-08-01 |
| 2017-05-28 | $1.00M 10-K · filed 2018-08-09 |
| 2016-05-29 | $2.30M 10-K/A · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |